IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, announced at a 60th anniversary
educational event that the Every Heartbeat Matters initiative has
exceeded the goal to impact the global burden of heart valve
disease by supporting the education, screening and treatment of one
million underserved people by 2020. With the support of grants from
Edwards Lifesciences Foundation and donations of Edwards heart
valve technologies, the initiative is now expected to reach a total
of 1.5 million underserved people globally by the 2020 target
through the cumulative effort of 60 non-profit partners.
"In 2014, we convened dozens of dedicated non-profit partners to
build a community focused on working collaboratively to tackle the
global health issue of heart valve disease for people with
significant health disparities," said Amanda Fowler, executive director, global
corporate giving, Edwards Lifesciences and Edwards Lifesciences
Foundation. "Bringing this community together has resulted in
meaningful connections that elevate the work being done to help
meet the needs of underserved patients. We have, and will continue
to invest the majority of our charitable giving to support this
community and to lead this charge in making an impact for at-risk
heart valve patients around the world."
"Millions of underserved people suffer from life-threatening
heart valve disease, with rheumatic heart disease and low-income
patients at the epicenter," said David H.
Adams, M.D., cardiac surgeon-in-chief, Mount Sinai Health
System; president, American Association for Thoracic Surgery;
president, Mitral Foundation. "The Every Heartbeat Matters
initiative is so much more than financial support. This community
is instrumental in helping us solve problems together, find new
approaches to care for underserved patients and learn from one
another."
Reporting and analytics of this initiative are measured with
rigor to ensure data are conservative and accurately reflect only
the impact in underserved populations. Since 2014, because of Every
Heartbeat Matters:
- 60 non-profit partners joined the initiative
- Approximately 900,000 underserved people have been impacted by
public health education
- More than 17,000 clinicians caring for underserved patients
have received training
- More than 80,000 underserved people have been screened for
heart valve disease
- Nearly 5,000 underserved people have received heart valve
treatment
- The initiative has reached underserved people in 36
countries
By 2020, the company and Edwards Lifesciences Foundation expect
to invest approximately $30 million
in this initiative. Partnerships are crucial to the continued
success of Every Heartbeat Matters. For more information on how new
potential partners can contribute to this initiative, please visit
EveryHeartbeatMatters.org.
Visit the Edwards YouTube site to learn more about the impact of
Every Heartbeat Matters and the journey of one patient,
Berthony Bertrand, who received the
transformative care he needed.
About Edwards Lifesciences and Edwards Lifesciences
Foundation
Edwards Lifesciences, based in Irvine, Calif., is the global leader in
patient-focused medical innovations for structural heart disease,
as well as critical care and surgical monitoring. Driven by a
passion to help patients, the company collaborates with the world's
leading clinicians and researchers to address unmet healthcare
needs, working to improve patient outcomes and enhance lives. For
more information, visit www.edwards.com and follow us on Twitter
@EdwardsLifesci. In 2004, the company established what is now
Edwards Lifesciences Foundation. The foundation focuses on
supporting underserved heart valve and critically ill patients, as
well as strengthening the communities in which Edwards employees
live and work. Since its inception, the foundation has gifted more
than $60 million to non-profit
organizations. Additional information can be found at
Edwards.com/CorporateGiving.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements by Dr. Adams
and Ms. Fowler and expectations regarding the potential timing and
scope of the initiative's impact. Forward-looking statements are
based on estimates and assumptions made by management of the
company and are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we
do not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of the
statement.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors, including but not limited to, unanticipated delays or
changes to the Every Heartbeat Matters initiatives. These and other
additional factors are detailed in the company's filings with the
Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31,
2017. These filings, along with important safety information
about our products, may be found at www.edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo and Every
Heartbeat Matters are trademarks of Edwards Lifesciences
Corporation. All other trademarks are the property of their
respective owners.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/edwards-lifesciences-philanthropy-exceeds-every-heartbeat-matters-goal-to-impact-one-million-underserved-people-ahead-of-schedule-300719169.html
SOURCE Edwards Lifesciences Corporation